STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more
Top of the morning to you, and a fine one it is. After two days…
Category: STAT+
STAT+: Amylyx to pull ALS drug from market, cut 70% of staff
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and…
STAT+: DNA test that predicts opioid addiction should be pulled off the market, critics urge the FDA
In the next 24 hours, more than 130 people will die from opioid-related drug overdoses….
STAT+: Mass. senators assail Steward Health Care during hearing on firm’s struggling hospitals
Senators Ed Markey and Elizabeth Warren on Wednesday slammed Steward Health Care and its embattled…
STAT+: Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines
LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start,…
STAT+: FDA approves TriClip for tricuspid heart valve disease, pitting Abbott against Edwards
The Food and Drug Administration approved a new device from Abbott meant to treat tricuspid…
STAT+: Pharmalittle: We’re reading about a White House drug-shortage plan, a Genmab deal, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Investors funnel $275 million into Paragon Therapeutics spinout
Investors have funneled $275 million into a revamped biotech developing new psoriasis and psoriatic arthritis…
STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials
For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing…
STAT+: Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies
LONDON — The Danish firm Genmab said Wednesday it would acquire ProfoundBio for $1.8 billion…
STAT+: The White House has a plan to stem drug shortages
WASHINGTON — The White House at long last published a plan to stem drug shortages,…
STAT+: Roivant CEO: New deals could ‘materialize later this year’
Can Roivant’s business model survive its success? Roivant Sciences announced two pieces of news Tuesday:…
STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Gritstone Bio says personalized cancer vaccine falls short in key trial
Gritstone Bio said Monday afternoon that its personalized cancer vaccine didn’t induce more responses than…
STAT+: FDA clears digital stethoscope company’s AI algorithm for heart failure
An AI algorithm to detect heart failure, embedded in a digital stethoscope, earned clearance from…
STAT+: Roivant autoimmune drug succeeds in Phase 2 study in eye condition
A drug being developed by a Roivant subsidiary for a range of autoimmune conditions succeeded…
Verve Therapeutics ‘pauses’ tests of its gene editor for heart disease and prioritizes a backup treatment
Verve Therapeutics said Tuesday that it is pausing testing of its closely watched gene-editing treatment…
STAT+: This AI company scans penis pictures for STIs. Its unproven tech is in an FDA gray zone
Artificial intelligence is already assessing decay in your teeth, abnormalities in your heart rhythm, and…
STAT+: Watch: Medicare billing forms are running out of space for growing health care prices
WASHINGTON — Health care costs are getting so high that prices are literally running off…
STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second…
STAT+: Biden administration sticks with slight cuts to 2025 Medicare Advantage payments
Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them…
.jpg)
STAT+: Otsuka’s digital treatment for depression cleared by FDA, as pharma tries to crack tricky market
The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder,…
STAT+: Pharmalittle: We’re reading about AstraZeneca’s CEO pay, an ALS drug spat in the U.K., and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Scientists uncover potential path to treating deadly childhood tumor
Most targeted cancer drugs work like tranquilizer darts, snaring an overzealous gene that has spurred…
STAT+: Critics say U.K. decision on ALS drug could have ‘chilling effect’ on access to new genetic medicines
LONDON — Neurologists and patient advocates are up in arms over a policy decision by…
STAT+: UnitedHealth’s surprising new target: Struggling Steward’s physician group
UnitedHealth Group has gobbled up physician practices at an astounding rate — roughly 20,000 last…
STAT+: Pharmalittle: We’re reading about Wegovy insurance coverage, Zepbound shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Washington wants to avert another Change Healthcare-like fiasco. Here’s what could be coming
Washington is cracking down on the technology running behind the scenes in health care following…
STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably
The financial ties between drug and device makers and some physicians remains pervasive, despite concerns…
STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock
This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Pharmalittle: We’re reading about a GLP-1 side effect, U.K. clinical trial transparency, and more
Top of the morning to you and a fine one it is. Despite cloudy skies…
STAT+: U.K. becomes the first country to release detailed data on sponsors that fail to register clinical trials
The United Kingdom has released comprehensive data showing which institutions have failed to register their…
STAT+: Why the world’s most expensive drug might not be all that overpriced
The staff of the Institute for Clinical and Economic Review, or ICER, are known as…
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
One of the indignities of getting older is the way your body’s defenses against microbes…
STAT+: Pharmalittle: We’re reading about abortion pill arguments, a Merck drug approval, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: AstraZeneca sues Arkansas over the role of pharmacies in a federal discount drug program
AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to…
STAT+: Steward Health Care has deal to sell doctor network to UnitedHealth
Troubled hospital operator Steward Health Care, grappling with a financial crisis that’s engulfed its eight…
STAT+: FDA is still struggling to inspect clinical research sites, watchdog finds
The U.S. Food and Drug Administration’s oversight of clinical research in hospitals and clinics has…
STAT+: Some nonprofit hospitals spend less on charity care than they receive in tax breaks, new analysis shows
A new study of hospitals’ charity care spending suggests nonprofit hospitals really aren’t that different…
STAT+: Roche subsidiary Foundation Medicine opens new headquarters in Boston
Contemporary paintings by artists who have overcome homelessness or disabilities greet visitors in the lobby….
.jpg)
STAT+: European antitrust regulators probe Zoetis over pain drug for dogs
The European Commission has opened a formal antitrust investigation to determine whether Zoetis, one of…
STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more
Rise and shine, everyone, another busy day is on the way. How so? The evidence…
STAT+: Amgen sues Colorado over its prescription drug affordability board
Amgen has filed a lawsuit accusing a Colorado state board of violating the U.S. Constitution…
STAT+: Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success
Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an…
STAT+: Merck drug for rare, deadly lung condition appears set for approval in U.S.
The Food and Drug Administration is expected to approve Merck’s drug to treat a rare…
STAT+: Chick-fil-A drops a ‘No Antibiotic Ever’ pledge on chicken over supply issues
Chick-fil-A, one of the largest fast-food restaurants in the U.S., is easing its commitment to…
STAT+: Vertex Pharmaceuticals is considering relocating its headquarters
When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that…
STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Novo Nordisk to acquire heart-disease focused Cardior Pharmaceuticals in deal worth $1.1 billion
LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in…
STAT+: Medicare Advantage insurers pressure Biden administration for bigger payments
The public will soon find out whether the federal government is willing to meet the…